{"article":{"annotation":{"article_id":"uk-mhra-triheptanoin-dojolvi-approval-2026","available_at":"2026-10-31T22:01:36.211578Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"c6944865be6c96dd64d9bafcb42a9c88c69e4e16307b305613c73da46fd5f86e","input_sha256":"1285223b9d6e34a9263589dbd95e81d7eb15556c5ac8a17798a19ef32154fa77","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"GB","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"]}],"geometry":null,"id":"iso3166-1:GB","kind":"country-or-area","labels":{"ar":"المملكة المتحدة لبريطانيا العظمى وآيرلندا الشمالية","en":"United Kingdom of Great Britain and Northern Ireland","es":"Reino Unido de Gran Bretaña e Irlanda del Norte","fr":"Royaume-Uni de Grande-Bretagne et d’Irlande du Nord"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: Healthcare","source_urls":["https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"]}],"method":"controlled-rules-v1","rule_id":"health","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=de","category":"health","content":{"key_points":[],"paragraphs":["Die britische Aufsichtsbehörde MHRA hat am 30. Oktober Triheptanoin (Dojolvi) als orale Flüssigkeit für Erwachsene und Kinder mit Störungen der Verwertung langkettiger Fettsäuren bedingt zugelassen.","Störungen der mitochondrialen Fettsäureoxidation sind seltene Erbkrankheiten, bei denen der Körper Fette nicht ordnungsgemäß in Energie umwandeln kann, was Kardiomyopathien, Rhabdomyolyse und schwere Hypoglykämien auslösen kann. Das synthetische mittelkettige Triglycerid Triheptanoin dient als alternative Energiequelle, die enzymatische Blockaden im Zitronensäurezyklus umgeht.","Die MHRA betonte, dass für eine uneingeschränkte Zulassung weitere pädiatrische Wirksamkeits- und Sicherheitsdaten eingereicht werden müssen. Zu den häufigsten Nebenwirkungen zählen Magen-Darm-Beschwerden wie Bauchschmerzen, Durchfall und Übelkeit. Die Zulassung regelt die klinische Anwendung unter diätetischer Fachaufsicht."],"sections":[]},"corrections":[],"country":"GB","data":{"blocks":[{"description":{"ar":"نشر إعلان ترخيص التسويق المشروط الرسمي في 30 أكتوبر 2026.","de":"Veröffentlichung der offiziellen Mitteilung zur bedingten Marktzulassung am 30. Oktober 2026.","en":"Publication of the official conditional marketing authorisation announcement on 30 October 2026.","es":"Publicación del anuncio oficial de autorización condicional de comercialización el 30 de octubre de 2026.","fr":"Publication de l’annonce officielle d’autorisation de mise sur le marché conditionnelle le 30 octobre 2026.","pt":"Publicação do anúncio oficial de autorização condicional de introdução no mercado em 30 de outubro de 2026.","tr":"30 Ekim 2026’da resmî şartlı pazarlama izni duyurusunun yayımlanması."},"id":"source-announcement","items":[{"date":"2026-10-30","description":{"ar":"إعلان الموافقة الرسمية في 30 أكتوبر 2026 لعلاج اضطرابات أكسدة الأحماض الدهنية طويلة السلسلة.","de":"Offizielle Zulassung am 30. Oktober 2026 zur Behandlung von Störungen der Fettsäureoxidation bekannt gegeben.","en":"Official approval announced on 30 October 2026 for treating long-chain fatty acid oxidation disorders.","es":"Aprobación oficial anunciada el 30 de octubre de 2026 para el tratamiento de trastornos de oxidación de ácidos grasos de cadena larga.","fr":"Approbation officielle annoncée le 30 octobre 2026 pour le traitement des troubles de l’oxydation des acides gras à chaîne longue.","pt":"Aprovação oficial anunciada em 30 de outubro de 2026 para o tratamento de distúrbios da oxidação de ácidos gordos de cadeia longa.","tr":"Uzun zincirli yağ asidi oksidasyon bozukluklarının tedavisi için 30 Ekim 2026'da resmî onay açıklandı."},"label":{"ar":"وكالة MHRA تصدر ترخيص تسويق مشروط لعقار تريهبتانوين","de":"MHRA erteilt bedingte Marktzulassung für Triheptanoin","en":"MHRA issues conditional marketing authorisation for triheptanoin","es":"La MHRA emite autorización de comercialización condicional para triheptanoína","fr":"La MHRA délivre une autorisation conditionnelle pour la triheptanoïne","pt":"MHRA emite autorização de introdução no mercado condicional para tri-heptanoína","tr":"MHRA, triheptanoin için şartlı pazarlama izni verdi"},"status":"occurred"}],"methodology":{"ar":"يسجل التاريخ يوم نشر المصدر الأولي المشار إليه. وتحدد المادة المؤشرات السريرية والضوابط التنظيمية.","de":"Das Datum bezeichnet die Veröffentlichung der angeführten Primärquelle. Klinische Indikationen und regulatorische Rahmenbedingungen werden im Artikel benannt.","en":"The date records publication of the cited primary source. Clinical indications and regulatory constraints are stated in the article.","es":"La fecha registra la publicación de la fuente primaria citada. El artículo identifica las indicaciones clínicas y las condiciones regulatorias.","fr":"La date correspond à la publication de la source primaire citée. Les indications cliniques et contraintes réglementaires sont précisées dans l’article.","pt":"A data regista a publicação da fonte primária citada. As indicações clínicas e condicionantes regulamentares são identificadas no artigo.","tr":"Tarih, atıf yapılan birincil kaynağın yayımlandığı günü gösterir. Klinik endikasyonlar ve düzenleyici kısıtlar haberde belirtilmiştir."},"sourceUrls":["https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"],"title":{"ar":"نشر المصدر","de":"Quellenveröffentlichung","en":"Source publication","es":"Publicación de la fuente","fr":"Publication de la source","pt":"Publicação da fonte","tr":"Kaynak yayını"},"type":"events","updatedAt":"2026-11-01T00:43:00Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026/data/source-announcement?lang=de&format=csv","json":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026/data/source-announcement?lang=de&format=json"},"id":"source-announcement"}],"data_types":["events"],"editorial_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-e7c50bae-6da6-56a7-bd4c-7b41c7c11b9d","event_period":"2026-10-30","event_period_basis":"event-or-reference-period","id":"uk-mhra-triheptanoin-dojolvi-approval-2026","image":null,"importance":0.6,"language":"de","modified_at":"2026-11-01T00:43:00Z","publication_basis":"publication-record","published_at":"2026-10-31T22:01:30+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"uk-mhra-triheptanoin-dojolvi-approval-2026","sources":[{"checkedAt":"2026-11-01","name":"Medicines and Healthcare products Regulatory Agency, United Kingdom","publishedAt":"2026-10-30","url":"https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders"}],"summary":"Die britische Aufsichtsbehörde MHRA hat am 30. Oktober Triheptanoin (Dojolvi) als orale Flüssigkeit für Erwachsene und Kinder mit Störungen der Verwertung langkettiger Fettsäuren bedingt zugelassen.","text":"Die britische Aufsichtsbehörde MHRA hat am 30. Oktober Triheptanoin (Dojolvi) als orale Flüssigkeit für Erwachsene und Kinder mit Störungen der Verwertung langkettiger Fettsäuren bedingt zugelassen.\n\nDie britische Aufsichtsbehörde MHRA hat am 30. Oktober Triheptanoin (Dojolvi) als orale Flüssigkeit für Erwachsene und Kinder mit Störungen der Verwertung langkettiger Fettsäuren bedingt zugelassen.\n\nStörungen der mitochondrialen Fettsäureoxidation sind seltene Erbkrankheiten, bei denen der Körper Fette nicht ordnungsgemäß in Energie umwandeln kann, was Kardiomyopathien, Rhabdomyolyse und schwere Hypoglykämien auslösen kann. Das synthetische mittelkettige Triglycerid Triheptanoin dient als alternative Energiequelle, die enzymatische Blockaden im Zitronensäurezyklus umgeht.\n\nDie MHRA betonte, dass für eine uneingeschränkte Zulassung weitere pädiatrische Wirksamkeits- und Sicherheitsdaten eingereicht werden müssen. Zu den häufigsten Nebenwirkungen zählen Magen-Darm-Beschwerden wie Bauchschmerzen, Durchfall und Übelkeit. Die Zulassung regelt die klinische Anwendung unter diätetischer Fachaufsicht.","title":"Britische MHRA erteilt bedingte Zulassung für Triheptanoin bei seltenen Stoffwechselstörungen","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},{"api_url":"https://newsverum.com/api/v1/articles/uk-mhra-triheptanoin-dojolvi-approval-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/uk-mhra-triheptanoin-dojolvi-approval-2026"}],"url":"https://newsverum.com/de/news/uk-mhra-triheptanoin-dojolvi-approval-2026"},"version":"1"}
